Xospata Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8969336 ASTELLAS Diamino heterocyclic carboxamide compound
Nov, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9487491 ASTELLAS Diamino heterocyclic carboxamide compound
Jul, 2030

(6 years from now)

US11944620 ASTELLAS Stable pharmaceutical composition for oral administration
Jul, 2036

(11 years from now)

US11938130 ASTELLAS Stable pharmaceutical composition for oral administration
Jul, 2036

(11 years from now)

US10786500 ASTELLAS Stable pharmaceutical composition for oral administration
Jul, 2036

(11 years from now)

US11938131 ASTELLAS Stable pharmaceutical composition for oral administration
Jul, 2036

(11 years from now)

US11938132 ASTELLAS Stable pharmaceutical composition for oral administration
Jul, 2036

(11 years from now)

US11938133 ASTELLAS Stable pharmaceutical composition for oral administration
Jul, 2036

(11 years from now)



Xospata is a drug owned by Astellas Pharma Us Inc. It is used for treating acute myeloid leukemia. Xospata uses Gilteritinib Fumarate as an active ingredient. Xospata was launched by Astellas in 2018. It is is available in tablet form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 01, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 28, 2023
Orphan Drug Exclusivity(ODE-222) Nov 28, 2025

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using GILTERITINIB FUMARATE ingredient

NCE-1 date: 28 November, 2022

Market Authorisation Date: 28 November, 2018

Treatment: Treatment of acute myeloid leukemia (aml)

Dosage: TABLET

How can I launch a generic of XOSPATA before it's drug patent expiration?
More Information on Dosage

XOSPATA family patents

Family Patents